Gas Chromatography for the Analysis of Drugs Michelle L

Total Page:16

File Type:pdf, Size:1020Kb

Gas Chromatography for the Analysis of Drugs Michelle L Seton Hall University eRepository @ Seton Hall Seton Hall University Dissertations and Theses Seton Hall University Dissertations and Theses (ETDs) Spring 5-16-2015 QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) Extraction – Gas Chromatography for the Analysis of Drugs Michelle L. Schmidt [email protected] Follow this and additional works at: https://scholarship.shu.edu/dissertations Part of the Analytical Chemistry Commons, and the Medicinal-Pharmaceutical Chemistry Commons Recommended Citation Schmidt, Michelle L., "QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) Extraction – Gas Chromatography for the Analysis of Drugs" (2015). Seton Hall University Dissertations and Theses (ETDs). 2060. https://scholarship.shu.edu/dissertations/2060 QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) Extraction – Gas Chromatography for the Analysis of Drugs BY Michelle L. Schmidt DISSERTATION Submitted to the Department of Chemistry and Biochemistry at Seton Hall University in partial fulfillment of the requirements for the degree of Doctor of Philosophy. May, 2015 1 © Michelle L. Schmidt 2015 2 We certify that we have read this dissertation and that in our opinion it is adequate to scientific scope and quality as a dissertation for the degree of Doctor of Philosophy. APPROVED _________________________________________________________ Nicholas H. Snow, Ph.D Research Mentor and Chair, Department of Chemistry and Biochemistry _________________________________________________________ Yuri V. Kazakevich, Ph.D Member of the Dissertation Committee _________________________________________________________ Sergiu M. Gorun, Ph.D Member of the Dissertation Committee 3 ACKNOWLEDGEMENTS I would like to thank Dr. Nicholas H. Snow for his continued guidance, input, and advice throughout my time at Seton Hall University and whose help was invaluable and deeply appreciated. He allowed me to become an independent, ‘think outside the box’ scientist and I cannot thank him enough. I would also like to thank Dr. Yuri Kazakevich and Dr. Sergiu Gorun for their input on both my dissertation and aid during my research. In addition to Drs. Snow, Kazakevich and Gorun, I would also like to thank Dr. Stephen Kelty and Dr. Cecelia Marzabadi, all of whom served on my matriculation committee and have provided research suggestions. I would like to thank Shimadzu, for their lending of the GC-MS/MS used in this research, and LECO, for their aid in use of the GCxGC-TOFMS. Both provided technical support, which was much appreciated. I would also like to thank Sanofi-Aventis and the Dr. Robert DeSimone Dissertation Fellowship in providing financial support for this research as well as the Philanthropic Educational Organization for the awarding of a $15,000 scholarship that was used toward my research. I would like to extend a special thanks to the Separation Science Group at Seton Hall University. Firstly, to those that I worked closest with in the lab throughout my time as a Ph.D. student, Dr. Brian Barnes, Dr. Shilpi Chopra, Dr. Ramkumar Dhandipani, Anumeha Muthal, Tom DelMastro, and Leanne Mocniak. The ability to work side by side and learn from each other was invaluable and I formed lasting friendships that I am extremely grateful to have. Lastly, I want to thank Julianne Berger and Nicole Curto, 4 who I met during my first year at Seton Hall. In them I truly found life long friends. We helped each other throughout our journey at Seton Hall and I don’t know how I would have gotten through it all without them. Most importantly, I would like to extend my greatest thanks and appreciation to my family and friends, particularly my mom, Joan; dad, Mike; sister, Andrea; fiancé, Rob; and past mentor, Dr. Lawrence Quarino, all of whom without this would not have been possible. They pushed me to be my best self and pursue my love of chemistry to obtain my Ph.D. They are the anchor that keeps my feet on the ground. It is because of them that I have the drive and passion to never give up on my dreams and always strive to accomplish my goals. Thank you mom and dad for shaping me into the person I am and for teaching me that if I work hard and put my mind to it, I can achieve anything. You gave me wings so I could fly. Finally, though they are no longer with me, my grandma and pop-pop always supported me in my dreams and endeavors and I hope I have made them proud. They are the wings that keep my heart in the clouds. 5 LIST OF FIGURES Figure 1-1. Structure of endcapped primary secondary amine (PSA) solid phase extraction (SPE) packing .................................................................................................. 26 Figure 1-2. Methodology of the LLE and clean up step for the original, AOAC 2007.01, and EN 15662 QuEChERS methods. Adapted from The UCT Pesticide Residue Analysis QuEChERS Information Booklet [8] ................................................................. 27 Figure 1-3. The three terms in the Van Deemter equation. A: eddy diffusion; B: longitudinal diffusion; C: mass transfer. Adapted from Y. Kazakevich Separations Introduction Lecture Slides [59] ...................................................................................... 52 Figure 1-4. The three terms in a Van Deemter plot (left) and the various gases as how they appear in the Van Deemter plot (right) ..................................................................... 53 Figure 1-5. Split (left) and splitless (right) injection. Adapted from Y. Kazakevich GC Injectors Lecture Slides [60]. ............................................................................................ 56 Figure 1-6. Schematic of an electron ionization (EI) source ............................................ 59 Figure 1-7. Schematic of a quadrupole mass analyzer. Adapted from P. Gates Gas Chromatography Mass Spectrometry (GC/MS): Figure 2 [61] ........................................ 60 Figure 1-8. Schematic of a continuous dynode electron multiplier. Adapted from J. Benedikt, A. Hecimovic, D. Ellerweg, and A. von Keudell. J Phys D-Appl Phys. 45(50) (2012) [62]. ....................................................................................................................... 61 Figure 2-1A. Overlaid chromatograms of a DCM-tea sample shake, LLE with ACN and salts, d-SPE with ACN and tea sample only, and the complete QuEChERS method ...... 74 Figure 2-1B. Top: Chromatogram depicting the peak area of caffeine at 5.704min without QuEChERS. Bottom: Chromatogram depicting the increased peak area of caffeine at 5.716min with QuEChERS as well as decreased matrix interference peaks .................... 75 Figure 2-2. Optimization of the pH during the initial sonication of lose tea in deionized water. ................................................................................................................................. 77 6 Figure 2-3. The effect of time on the initial sonication time of loose tea in deionized water (left) and the resulting plot of peak area vs. time as a kinetic study. ...................... 78 Figure 2-4. The effect of temperature during the initial sonication of loose tea in deionized water as a thermodynamic study. .................................................................... 79 Figure 2-5. The effect of the salt ratio on the amount of organic solvent separated from the aqueous phase and the extraction of matrix interferences .......................................... 81 Figure 2-6. Optimization of salt ratio amount during the LLE step of the QuEChERS method ............................................................................................................................... 82 Figure 2-7. Optimization of the salt type during the LLE step of the QuEChERS method. ........................................................................................................................................... 83 Figure 2-8. Optimization of the ratio of organic solvent to aqueous tea sample during the LLE step of the QuEChERS method. ............................................................................... 86 Figure 2-9. Optimization of the organic solvent type during the LLE step of the QuEChERS method. ......................................................................................................... 87 Figure 2-10. The effect of time on the sonication time during the LLE step in the QuEChERS method (left) and the resulting plot of peak area vs. time as a kinetic study. ........................................................................................................................................... 89 Figure 2-11. The effect of time on the sonication time during the d-SPE step in the QuEChERS method (left) and the resulting plot of peak area vs. time as a kinetic study. ........................................................................................................................................... 90 Figure 2-12. The effect of temperature during the LLE step in the QuEChERS method. 92 Figure 2-13. The effect of temperature during the d-SPE step in the QuEChERS method. ........................................................................................................................................... 93 Figure 2-14. Calibration curve from the method validation of the optimized QuEChERS extraction. .......................................................................................................................... 95 Figure 2-15. Linearity of caffeine from the method validation of the
Recommended publications
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Ranvet's Filybol
    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Rapid Rise in Toxic Load for Bees Revealed by Analysis of Pesticide Use in Great Britain
    A peer-reviewed version of this preprint was published in PeerJ on 19 July 2018. View the peer-reviewed version (peerj.com/articles/5255), which is the preferred citable publication unless you specifically need to cite this preprint. Goulson D, Thompson J, Croombs A. 2018. Rapid rise in toxic load for bees revealed by analysis of pesticide use in Great Britain. PeerJ 6:e5255 https://doi.org/10.7717/peerj.5255 Rapid rise in toxic load for bees revealed by analysis of pesticide use in Great Britain Dave Goulson Corresp., 1 , Jack Thompson 1 , Amy Croombs 1 1 School of Life Sciences, University of Sussex, University of Sussex, Falmer, E Sussex, United Kingdom Corresponding Author: Dave Goulson Email address: [email protected] A strong argument can be made that the European Union has the most rigorous regulatory system for pesticides in the world, and that modern pesticide use poses fewer environmental threats than older regimes. Nevertheless, the impacts of pesticides on bees and other non-target organisms is much debated in Europe as elsewhere. Here we document changing patterns of pesticide use in arable and horticultural crops in Great Britain from 1990 to 2015. The weight of pesticides used has approximately halved over this period, but in contrast the number of applications per field nearly doubled. The total potential kill of honeybees (the total number of LD50 doses applied to the 4.6 million hectares of arable farmland in Great Britain each year) increased six-fold to approximately 3 x 1016 bees, the result of the increasing use of neonicotinoids from 1994 onwards which more than offset the effect of declining organophosphate use.
    [Show full text]
  • APPLICATION of Quechers METHOD for MULTI-RESIDUE PESTICIDES DETERMINATION in LETTUCE and APPLE USING GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    Nigerian Journal of Technology (NIJOTECH) Vol. 35, No. 3, July 2016, pp. 544 – 549 Copyright© Faculty of Engineering, University of Nigeria, Nsukka, Print ISSN: 0331-8443, Electronic ISSN: 2467-8821 www.nijotech.com http://dx.doi.org/10.4314/njt.v35i3.11 APPLICATION OF QuEChERS METHOD FOR MULTI-RESIDUE PESTICIDES DETERMINATION IN LETTUCE AND APPLE USING GAS CHROMATOGRAPHY-MASS SPECTROMETRY J. Ukpebor1,* and E. Ukpebor2 1LANCASTER ENVIRONMENT CENTRE, LANCASTER UNIVERSITY, LANCASTER LA1 4YQ, UNITED KINGDOM 2CHEMISTRY DEPARTMENT, FACULTY OF PHYSICAL SCIENCES, UNIVERSITY OF BENIN, BENIN CITY, EDO STATE NIGERIA E-mail addresses: 1 [email protected] , 2 [email protected] ABSTRACT This study investigated the use of the QuEChERS method for the analysis of 13 pesticides on apples and lettuces. Comparison between two methods: Citrate- (buffered and unbuffered) and acetate (buffered and unbuffered). A range of pesticides –pirimicarb, diazinon, chlorpyrifos, azoxystrobin, pendimethalin, cyprodinil, boscalid, chlorothalonil, fenhexamid were selected for this study. Triphenyl phosphate was used as the internal standard. Results obtained revealed very high percentage recoveries for the majority of the pesticides screened for with recoveries of 66.3 to 109.8% for the citrate buffered, 72.5 – 120.8% for citrate unbuffered, 53.8 – 102% for acetate buffered and 54 – 105.3% for acetate unbuffered experiments carried out using apple samples. % recoveries obtained for the lettuce samples were 32.2 to 120.5% for the citrate buffered, 33.7 – 115.0% for citrate unbuffered, 53.8 – 107.4% for acetate buffered and 54 – 105.3% for acetate unbuffered experiments. % recoveries obtained for the apple samples were 64.3 – 109.8% for the citrate buffered, 72.5 – 120.8% for the citrate unbuffered, 60.3 – 102.0% for the acetate buffered and 54 – 120.5% for acetate unbuffered.
    [Show full text]
  • Ranvet's Filybol
    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 01/24/2018 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified uses Non-virilising anabolic combination for fillies, mares, colts and stallions. Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Legend: Annex VI Label elements Hazard pictogram(s) SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 01/24/2018 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
    [Show full text]
  • Permanent Ban on Anabolic Androgenic Steroids From
    Permanent Ban on Anabolic Androgenic Steroids to be introduced into the Greyhounds Australasia Rules Warning to trainers – Anabolic Androgenic Steroids (AAS) usage in greyhounds On 1 January 2016, Greyhounds Australasia will introduce Anabolic Androgenic Steroids to the list of Permanently Banned Prohibited Substances within GAR 79A (2) xx. as follows: “Anabolic androgenic steroids excluding those that are defined as an exempted substance pursuant to GAR 1.” The relevant exempted substance listed within GAR 1 is as follows: “Ethyloestrenol when administered orally to a greyhound bitch and where it has been prescribed by a veterinary surgeon for the sole purpose of regulating or preventing oestrus in that bitch.” Participants are advised that in accordance with GAR 79A they must never possess, acquire, attempt to acquire, administer or allow to be administered to any greyhound from birth until retirement, any anabolic androgenic steroid, excluding ethyloestrenol where it is appropriately prescribed for use as an oestrous suppressant in females. “Anabolic androgenic steroids” include those that are currently registered in Australia by the APVMA such as boldenone, ethyloestrenol, methandriol, nandrolone, stanozolol and testosterone. Others include but are not limited to 1- androstenediol; 1-androstenedione; bolandiol; bolasterone; boldione; calusterone; clostebol; danazol; dehydrochlormethyltestosterone; desoxymethyltestosterone; drostanolone; fluoxymesterone; formebolone; furazabol; gestrinone; 4-hydroxytestosterone; mestanolone; mesterolone;
    [Show full text]
  • 2004 Prohibited List
    The World Anti-Doping Code THE 2004 PROHIBITED LIST INTERNATIONAL STANDARD (update 17 March 2004) This List shall come into effect on 26 March 2004. THE 2004 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 26 March 2004 (Updated 17 March 2004) SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES S1. STIMULANTS The following stimulants are prohibited, including both their optical (D- and L-) isomers where relevant: Adrafinil, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, bromantan, carphedon, cathine*, clobenzorex, cocaine, dimethylamphetamine, ephedrine**, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, fenproporex, furfenorex, mefenorex, mephentermine, mesocarb, methamphetamine, methylamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, methylephedrine**, methylphenidate, modafinil, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, phendimetrazine, phenmetrazine, phentermine, prolintane, selegiline, strychnine, and other substances with similar chemical structure or similar pharmacological effect(s)***. * Cathine is prohibited when its concentration in urine is greater than 5 micrograms per millilitre. ** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per millilitre. *** The substances included in the 2004 Monitoring Program are not considered as Prohibited Substances. The Prohibited List 2004 1 26 March 2004 S2. NARCOTICS The following narcotics are prohibited: buprenorphine, dextromoramide,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • Anabolic Steroid Use, Misuse and Addiction
    Anabolic Steroid Use, Misuse And Addiction Introduction Anabolic steroids have an important role to play in the treatment of medical conditions. There is, however, an illicit use of anabolic steroids. Today, most athletes, involved in sports activities that require greater strength, take anabolic steroids to increase their weight and strength. These sports include competitive sports like weight lifting, wrestling, and other strength based contests. In addition, people who are obsessed about having a “perfect” physical appearance also misuse anabolic steroids. The number of individuals using anabolic steroids for sports or to improve their looks is growing. This increased use of anabolic steroids is driven by the perception that they may give a person an edge when it comes to sports activities. Unfortunately, many individuals use anabolic steroids without regard for the disastrous impacts it can have on their bodies. Anabolic Steroids And Testosterone: An Overview Anabolic steroids are an androgenic hormone, and is also known by its proper name anabolic-androgen steroids (AAS). Testosterone is a natural anabolic steroid and it is the primary sex hormone in males. In order to understand anabolic steroids, it is important to know how testosterone works. Testosterone is vital for the development of reproductive organs like the prostate and testes. It enhances male sexual features such as increased bone mass, muscles and body hair growth.1 Testosterone also promotes health and overall wellbeing. For example, it helps ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com 1 prevent osteoporosis. Many abnormalities in the body, such as bone loss or frailty, are associated with testosterone deficiency.2 Synthetic anabolic steroids are an artificial form of the male hormone testosterone.
    [Show full text]
  • Anti-Doping Manual Revised Dec. 2018
    PGA TOUR Anti-Doping Program Manual REVISED DECEMBER 2018 Table of Contents How To Use This Manual .......................................................................................................................................................2 SECTION 1: Player Guide To Anti-Doping ...........................................................................................................................3 Who is covered by the Anti-Doping Program .........................................................................................................3 What substances and methods are banned ..........................................................................................................3 Am I liable for a prohibited substance in my body even if I did not intend to take the substance ........................3 What should players know about nutritional and health products ...................................................................3 Are there supplements that have been tested/certified as free from banned substances ........................3 What about medical treatment.................................................................................................................................4 What medications are permitted .............................................................................................................................4 Who conducts the testing and who will be tested ................................................................................................4 What are the steps in
    [Show full text]